Figures & data
Figure 1. The reported Myt1 glycoglycerolipid inhibitor GGL1 did not have any effect in a fluorescence anisotropy-based Myt1 kinase binding assay. Anisotropies were normalized against positive controls (10 µM dasatinib; displacement 100%) and vehicle (1% DMSO; displacement 0%). Data represent means ± SEM (n = 3).
Figure 2. Representative Western blot results for investigations on the inhibitory properties of the glycoglycerolipid GGL1 (30 µg/ml) on full-length Myt1. Myt1 phosphorylates Cdk1 at Tyr-15 (compare lanes 1 and 2). GGL1 does not alter the extent of phosphorylation (lane 3). Dasatinib (10 µM) was used as an inhibition control and efficiently suppresses Cdk1-phosphorylation (lane 4). Myt1 and Cdk1 were present in all samples.
